Fanconi Anemia - Pipeline Insight, 2022

DelveInsight's , "Fanconi Anemia - Pipeline Insight, 2022," report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Fanconi Anemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Fanconi Anemia Understanding

Fanconi Anemia: Overview

Fanconi anemia (FA) is a rare genetic disorder, involving all three blood cell lines. It is the most common cause of inherited bone marrow failure characterized by pancytopenia. Additionally, it affects almost all organs of the body. Fanconi anemia is mainly based upon the molecular mechanism involving a defective homologous recombination DNA repair pathway, defects in proteins as well as other enzymes involved in the repair of damaged DNA following various alkylating agents, irradiation, and cytotoxic drugs. It is also referred to as the inherited form of aplastic anemia. The discovery of Fanconi anemia had implications far beyond the disease itself. An extensive study of other bone marrow failure syndromes and chromosome fragility diseases has enhanced the scientific understanding of the bone marrow failure in Fanconi anemia. It is mostly associated with other congenital deformities and is susceptible to hematological and solid tumors. It usually is more common during childhood, with the average age of diagnosis being 7 years. The advancement of molecular genetic studies has helped in the comprehensive study of Fanconi anemia.

"Fanconi Anemia - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Fanconi Anemia pipeline landscape is provided which includes the disease overview and Fanconi Anemia treatment guidelines. The assessment part of the report embraces, in depth Fanconi Anemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Fanconi Anemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Fanconi Anemia.

• In the coming years, the Fanconi Anemia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

• The companies and academics that are working to assess challenges and seek opportunities that could influence Fanconi Anemia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

• A detailed portfolio of major pharma players who are involved in fueling the Fanconi Anemia treatment market. Several potential therapies for Fanconi Anemia are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Fanconi Anemia market size in the coming years.

• Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Fanconi Anemia) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Fanconi Anemia Emerging Drugs Chapters

This segment of the Fanconi Anemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Fanconi Anemia Emerging Drugs

Mozafancogene autotemcel: Rocket Pharmaceuticals

Mozafancogene autotemcel (formerly RP L102) is a lentiviral vector-based gene therapy, developed by Rocket Pharmaceuticals for the treatment of Fanconi's. Currently, it is in Phase II stage of clinical trial evaluation.

FP-045: Foresee Pharmaceuticals

FP-045 is a potent and highly selective aldehyde dehydrogenase (ALDH2) activator, highly soluble and orally available. ALDH2 is a key mitochondrial regulator of toxic aldehyde metabolism. FP-045 has successfully completed single and multiple ascending dose Phase 1 studies. In vitro, FP-045 increases ALDH2 activity in FANCA-deficient cells and protects FANCA-deficient cells from damage due to exposure to toxic reactive aldehyde such as 4-HNE. FP-045 also decreases TNF-α release from cultured FA lymphocytes. These data support that ALDH2 activity may be important in maintaining the development of blood cells in Fanconi anemia patients and as such may be a useful treatment for patients with incipient bone marrow failure.

Further product details are provided in the report:

Fanconi Anemia: Therapeutic Assessment

This segment of the report provides insights about the different Fanconi Anemia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Fanconi Anemia

There are approx. 4+ key companies which are developing the therapies for Fanconi Anemia. The companies which have their Fanconi Anemia drug candidates in the most advanced stage, i.e. phase II include, Rocket Pharmaceuticals.

Phases

DelveInsight's report covers around 4+ products under different phases of clinical development like:

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Fanconi Anemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as:

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Fanconi Anemia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Fanconi Anemia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Fanconi Anemia drugs.

Fanconi Anemia Report Insights

• Fanconi Anemia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Fanconi Anemia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Fanconi Anemia drugs?

• How many Fanconi Anemia drugs are developed by each company?

• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Fanconi Anemia?

• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Fanconi Anemia therapeutics?

• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

• What are the clinical studies going on for Fanconi Anemia and their status?

• What are the key designations that have been granted to the emerging drugs?

Key Players

• Rocket Pharmaceuticals
• Foresee Pharmaceuticals
• Elixirgen
• Genethon
• Spotlight Therapeutics

Key Products

• Mozafancogene autotemcel
• FP-045
• EXG 34217